Virtual Library
Start Your Search
Linda Coate
Author of
-
+
OA10 - Right Patient, Right Target & Right Drug - Novel Treatments and Research Partnerships (ID 910)
- Event: WCLC 2018
- Type: Oral Abstract Session
- Track: Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 10:30 - 12:00, Room 106
-
+
OA10.08 - Discussant - OA 10.04, OA 10.05, OA 10.06, OA 10.07 (ID 14565)
11:45 - 12:00 | Presenting Author(s): Linda Coate
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
P2.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 964)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.15-19 - Inequality of Access to Novel Lung Cancer Therapies in Europe (ID 13058)
16:45 - 18:00 | Author(s): Linda Coate
- Abstract
Background
With an estimated incidence of over 449,000 cases per year, lung cancer is one of the most common malignancies in Europe. Over the last decade the landscape of lung cancer treatment has evolved. We have entered a new era of lung cancer treatment and high costs has led to disparities in lung cancer care among different European countries. There is evidence of discrepancy in access to cancer therapies in Europe however access to contemporary targeted agents and immunotherapy for lung cancer hasn’t been studied. We analysed the reimbursement dates of novel lung cancer therapies in Europe.
a9ded1e5ce5d75814730bb4caaf49419 Method
The lung cancer therapies investigated include the tyrosine kinase inhibitors (TKI) alectinib, ceritinib, and crizotinib. Immunotherapy agents nivolumab, pembrolizumab and atezolizumab were also researched. National reimbursement dates of these drugs of these drugs in 29 European countries were obtained from national resources and from the pharmaceutical companies’ affiliates.
4c3880bb027f159e801041b1021e88e8 Result
As of February 2018, Crizotinib was reimbursed in 24/29 (83%) of countries. Ceritinib was reimbursed in 21/29 (72%) of countries while Alectinib was reimbursed in 12/29 (41%) countries. Pembrolizumab and Nivolumab were reimbursed for previously treated NSCLC in 21/29 (72%) and 18/29 (62%) countries respectively. Atezolizumab was reimbursed in 7/29 (24%) countries for previously treated NSCLC patients. Pembrolizumab for first line treatment of NSCLC was reimbursed in 20/29 (69%) countries, while in 9/29 (31%) (all Eastern European Countries) not reimbursed. Eastern European countries reimbursed these drugs later than Western European countries.
8eea62084ca7e541d918e823422bd82e Conclusion
The time from European Medicines Agency approval to reimbursement of these novel lung cancer treatments differs throughout Europe. Eastern European countries were less likely to have novel lung cancer therapies reimbursed. This research shows access to novel lung cancer therapeutics is unbalanced in Europe.
6f8b794f3246b0c1e1780bb4d4d5dc53
